I got my first taste of this industry as an intern at Schering-Plough's Managed Care group.
Virginia Carden Carnahan
Vice President, New Product Planning and Strategy, Vertex Pharmaceuticals
I got my first taste of this industry as an intern at Schering-Plough's Managed Care group. After finishing my MBA at Duke University's Fuqua School of Business, I joined Schering Plough's oncology marketing team for Intron A. Afterward, I took a field sales rotation during the launch of Claritin. The field experience helped me to better understand which marketing strategies help deliver data clearly to physicians and patients.
Now I head up the New Product Planning and Strategy group at Vertex Pharmaceuticals. Essentially, we are interpreters. We collect customer insights, unmet needs, and communicate these to the research and development organizations within Vertex. This helps to shape the discovery and development of compounds that are aligned with the unmet needs of patients.
The pharma industry must discover new ways to address patient needs with new medicines, and ensure that they are accessible to those patients. To ensure that access, we need to develop strong value propositions for payers to complement the benefit/risk ratio for patients and physicians. Industry also needs to address the changing environment, and the current lack of trust between our industry and society. We need to rethink our strategies, and that may require new leadership to challenge the traditional approach.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.